

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **Jaume Pons** :

APPLICATION NO.: **10/584,443** : Examiner: **Virginia Lirby**

FILING DATE: **June 21, 2006** : Group Art Unit: **1643**

TITLE: **AGONIST ANTI-trkC ANTIBODIES AND** :
METHODS USING SAME

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Sir:

In response to the Notification of Defective Response under 35 U.S.C. 371 in the United States Designated/Elected Office mailed January 22, 2008, Applicant submits herewith the following:


1. A copy of the Sequence Listing in computer readable form in compliance with the requirements of 37 CFR 1.822 and/or 1.823.
2. Statement that the content of the sequence listing information in the computer readable form is identical to the written sequence listing, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).
3. Petition for Extension of Time.

The Office is authorized to debit Account No. 16-1445 in payment of the outstanding fees including:

- a. Additional claim fees of \$420.00 for a large entity
- b. The fee of \$2,230.00 for five months extension of time.

Respectfully submitted,

Date: July 15, 2008



Nicholas J. Slepchuk, Jr.
Attorney for the Applicant
Reg. No. 32,174

Pfizer Inc.
Patent Department
Eastern Point Road MS8260-1611
Groton, CT 06340
Telephone: (860)715-0081